🇪🇺 Methylnaltrexone (MNTX) in European Union

EMA authorised Methylnaltrexone (MNTX) on 1 July 2008

Marketing authorisation

EMA — authorised 1 July 2008

  • Application: EMEA/H/C/000870
  • Marketing authorisation holder: Bausch Health Ireland Limited
  • Local brand name: Relistor
  • Indication: Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
  • Status: approved

Read official source →

Methylnaltrexone (MNTX) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Methylnaltrexone (MNTX) approved in European Union?

Yes. EMA authorised it on 1 July 2008.

Who is the marketing authorisation holder for Methylnaltrexone (MNTX) in European Union?

Bausch Health Ireland Limited holds the EU marketing authorisation.